Emeis Stock Bounces Back by 2% and Crosses Above a Key Technical Threshold
The healthcare services group's stock rebounds in mid-afternoon, after several turbulent sessions. The stock regains strength in a notably bullish SBF 120, partially erasing its monthly decline. The movement marks a technical crossing that has been monitored since the start of the month.
A Rebound Bringing the Price Above Its 20-Day Moving Average
Emeis stock gains 2.15% to €14.26 during the session, in an SBF 120 that is up by 0.67%. The stock crosses above its 20-day moving average (€14.12), with a modest gap of +0.99%, while the price remains above its 200-day moving average at €13.97 (+2.08% gap). The 50-day moving average at €14.39 is the next hurdle, with the stock price just below it. The RSI at 42 remains neutral, showing no signs of extension, and the MACD is approaching its signal line. The rebound follows a test of the support at €13.64 yesterday, where the stock briefly dipped below its technical threshold before recovering. Over the week, the performance is up by 4.16%, which mitigates the nearly 3% monthly decline. Over three months, the stock maintains a gain of nearly 10%, and 25.86% over one year.
A Bullish Session in an SBF 120 Boosted by Brent's Easing
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Emeis is among the top gainers in the SBF 120 during the session, though not ranking at the very top where Soitec, Trigano, and STMicroelectronics lead. The rebound is part of a Parisian market trending upwards, with the CAC 40 at 8,441.83 points (+0.67%) and a VIX down more than 8% at 17.87. The easing of oil prices, with Brent crude returning to around $72.5 following the resumption of flows through the Strait of Hormuz, alleviates the geopolitical risk premium on European assets. The recent stock sequence remains turbulent, alternating between rebounds and declines. The resistance threshold at €15.33 now marks the next identified level above the current price.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 543 millions d'euros
Quarterly revenue: 4 543 millions d'euros
Revenue growth: 3,5 %
Guidance from the release
« Les tendances observées lors des 9 premiers mois de l'année 2026 confortent emeis dans l'atteinte des objectifs pour 2026, objectifs par ailleurs relevés fin juillet. »
Risks mentioned
Health crises linked to flu outbreaks and heat waves requiring proactive management
Macroeconomic uncertainty and risk of return to inflation impacting operating expenses
Dependency on continued execution of operational efficiency programs such as the Boost initiative in France
Opportunities identified
Strong like-for-like revenue growth of +6.0% driven by improved occupancy rates and favorable pricing effects
Average occupancy rate now above 90% with +2.9 pts annual increase, particularly strong in nursing homes (+3.1 pts)
Structural demographic tailwind with European senior population aged 85+ expected to grow over 30% in next 10 years
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
